US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Intensity Therapeutics, Inc.

3.77

-0.2200-5.51%

Post-market: 3.770.00000.00%19:24 EDT

Volume:19.52K

Turnover:73.27K

Market Cap:10.19M

PE:-0.94

High:3.82

Open:3.81

Low:3.70

Close:3.99

52wk High:43.50

52wk Low:3.70

Shares:2.70M

Float Shares:2.48M

Volume Ratio:0.43

T/O Rate:0.79%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.0100

EPS(LYR):-8.5567

ROE:-207.37%

ROA:-90.39%

PB:1.02

PE(LYR):-0.44

Loading ...

Overview Company News Filings

Intensity Therapeutics Q1 FY26 net loss narrows to $2.4 million

BRIEF-Intensity Therapeutics Q1 Operating Income USD -2.526 Million

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS

Intensity Therapeutics announces annual shareholder meeting webcast

Intensity Therapeutics Inc : Benchmark Adjusts Target Price to $12 From $1.50 to Reflect Reverse Stock Split

THOMSON REUTERS

U.S. Tariff and Trade Policy Risks Threaten Intensity Therapeutics’ Supply Chain, Costs, and Stock Valuation

Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update

THOMSON REUTERS

Intensity Therapeutics FY2025 net loss narrows 28.66% to $(11.6) million; operating expenses drop 27.81% to $12.0 million

Intensity Therapeutics issued new patent in the US

Intensity Therapeutics wins US patent 12,496,345 for cancer treatment method

Intensity Therapeutics Inc Files for Common Stock Offering of up to $60 Mln - SEC Filing

THOMSON REUTERS

Intensity Therapeutics expands ATM equity offering capacity to USD 60 million

Intensity Therapeutics Inc - Expanded Atm Facility Intended to Enhance Financial Flexibility - SEC Filing

THOMSON REUTERS

Alliance Global Partners Sticks to Their Buy Rating for Intensity Therapeutics, Inc. (INTS)

BUZZ-U.S. STOCKS ON THE MOVE -Natera, Pacira BioSciences, Kezar Life Sciences

Intensity Therapeutics Updates Breast Cancer Trial, Files To Resume Enrollment Following Study Pause

BUZZ-Intensity Therapeutics rises as breast cancer drug shows early promise

Intensity Therapeutics reports 71% pCR in INT230-6 arm and 44% fewer grade 3+ adverse events in INVINCIBLE-4 study

Intensity Therapeutics Inc - Protocol Amendment Proposes Lower Drug Volume and Single Int230-6 Injection

THOMSON REUTERS

Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer Invincible-4 Study

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/INTS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"INTS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INTS\",,,,,undefined,":{"symbol":"INTS","market":"US","secType":"STK","nameCN":"Intensity Therapeutics, Inc.","latestPrice":3.77,"timestamp":1780689600000,"preClose":3.99,"halted":0,"volume":19517,"hourTrading":{"tag":"盘后","latestPrice":3.77,"preClose":3.77,"latestTime":"19:24 EDT","volume":35,"amount":132.38,"timestamp":1780701895442,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.05513784461152887,"floatShares":2481700,"shares":2702820,"eps":-4.01,"marketStatus":"Closed","change":-0.22,"latestTime":"06-05 16:00:00 EDT","open":3.81,"high":3.82,"low":3.7,"amount":73268.6408878,"amplitude":0.030075,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.01,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1780905600000},"marketStatusCode":5,"adr":0,"listingDate":1666324800000,"exchange":"NASDAQ","adjPreClose":3.99,"preHourTrading":{"tag":"盘前","latestPrice":3.9,"preClose":3.99,"latestTime":"09:29 EDT","volume":943,"amount":3692.7901689,"timestamp":1780666145721,"change":-0.09,"changeRate":-0.022556,"amplitude":0.065163},"postHourTrading":{"tag":"盘后","latestPrice":3.77,"preClose":3.77,"latestTime":"19:24 EDT","volume":35,"amount":132.38,"timestamp":1780701895442,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.432188},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INTS\",,,,,undefined,":{"symbol":"INTS","floatShares":2481700,"roa":"-90.39%","roe":"-207.37%","lyrEps":-8.556737,"volumeRatio":0.432188,"shares":2702820,"dividePrice":0,"high":3.82,"amplitude":0.030075,"preClose":3.99,"low":3.7,"week52Low":3.7,"pbRate":"1.02","week52High":43.5,"institutionHeld":0,"latestPrice":3.77,"eps":-4.01,"divideRate":0,"volume":19517,"delay":0,"ttmEps":-4.01,"open":3.81,"prevYearClose":10.255,"prevWeekClose":4.39,"prevMonthClose":4.39,"prevQuarterClose":5.88,"fiveDayClose":4.39,"twentyDayClose":5.11,"sixtyDayClose":7.91},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/INTS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-02-19","symbol":"INTS","defaultRemindTime":1771511400000,"type":"split","dateTimestamp":1771477200000,"forFactor":25,"toFactor":1,"ratio":25}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"INTS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"INTS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":5,"updateTime":1774929600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/INTS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"INTS","date":"2026-06-04","current":-0.950125,"percent":0.871831,"low":-15.25821,"twenty":-5.984355,"median":-2.391613,"eighty":-1.140453,"high":-0.31723,"avg":-3.741469,"sd":3.20896,"marketCap":10651339},"quantilePoints":[{"date":"2022-10-20","current":-9.173693,"twenty":-9.173693,"median":-9.173693,"eighty":-9.173693,"marketCap":80934718},{"date":"2023-07-07","current":-12.000673,"twenty":-12.000673,"median":-11.893737,"eighty":-9.173693,"marketCap":78596262},{"date":"2023-07-14","current":-11.805305,"twenty":-12.014248,"median":-11.893737,"eighty":-11.600651,"marketCap":77316730},{"date":"2023-07-21","current":-12.682867,"twenty":-12.306769,"median":-11.947205,"eighty":-11.660654,"marketCap":83064168},{"date":"2023-07-28","current":-11.867988,"twenty":-12.682867,"median":-12.014248,"eighty":-11.805305,"marketCap":77727261},{"date":"2023-08-04","current":-12.81868,"twenty":-12.682867,"median":-12.066484,"eighty":-11.867988,"marketCap":83953652},{"date":"2023-08-11","current":-12.933599,"twenty":-12.933599,"median":-12.306769,"eighty":-11.888882,"marketCap":84706293},{"date":"2023-08-18","current":-9.652146,"twenty":-12.81868,"median":-12.1197,"eighty":-11.660654,"marketCap":80327292},{"date":"2023-08-25","current":-9.800135,"twenty":-12.808233,"median":-12.000673,"eighty":-9.800135,"marketCap":81558886},{"date":"2023-09-01","current":-9.487714,"twenty":-12.770623,"median":-11.912204,"eighty":-9.783692,"marketCap":78958855},{"date":"2023-09-08","current":-9.093078,"twenty":-12.755579,"median":-11.893737,"eighty":-9.638992,"marketCap":75674604},{"date":"2023-09-15","current":-8.073601,"twenty":-12.70794,"median":-11.836647,"eighty":-9.487714,"marketCap":67190291},{"date":"2023-09-22","current":-6.034647,"twenty":-12.632721,"median":-11.600651,"eighty":-9.000996,"marketCap":50221663},{"date":"2023-09-29","current":-6.626601,"twenty":-12.586753,"median":-9.923459,"eighty":-8.293939,"marketCap":55148039},{"date":"2023-10-06","current":-7.251442,"twenty":-12.570873,"median":-9.800135,"eighty":-7.560574,"marketCap":60348102},{"date":"2023-10-13","current":-6.626601,"twenty":-12.448015,"median":-9.783692,"eighty":-7.192246,"marketCap":55148039},{"date":"2023-10-20","current":-4.636976,"twenty":-12.331842,"median":-9.61926,"eighty":-6.745518,"marketCap":38589943},{"date":"2023-10-23","current":-4.96584,"twenty":-12.319306,"median":-9.578152,"eighty":-6.686849,"marketCap":41326818},{"date":"2023-11-03","current":-4.932954,"twenty":-12.157898,"median":-9.487714,"eighty":-6.567406,"marketCap":41053131},{"date":"2023-11-10","current":-4.609845,"twenty":-12.119112,"median":-9.173693,"eighty":-6.48519,"marketCap":38364150},{"date":"2023-11-17","current":-3.237228,"twenty":-12.035142,"median":-8.862874,"eighty":-6.287872,"marketCap":28737191},{"date":"2023-11-24","current":-3.590621,"twenty":-12.006103,"median":-8.517567,"eighty":-5.189368,"marketCap":31874301},{"date":"2023-12-01","current":-3.784438,"twenty":-11.971208,"median":-8.209257,"eighty":-5.01517,"marketCap":33594828},{"date":"2023-12-08","current":-6.177413,"twenty":-11.939029,"median":-7.613192,"eighty":-5.01517,"marketCap":54837508},{"date":"2023-12-15","current":-12.447487,"twenty":-12.056037,"median":-8.209257,"eighty":-5.034902,"marketCap":110497578},{"date":"2023-12-22","current":-9.544103,"twenty":-12.056037,"median":-8.517567,"eighty":-5.074891,"marketCap":84723949},{"date":"2023-12-29","current":-12.200391,"twenty":-12.097826,"median":-8.854652,"eighty":-5.093498,"marketCap":108304078},{"date":"2024-01-05","current":-12.586479,"twenty":-12.221667,"median":-9.093078,"eighty":-5.095649,"marketCap":111731422},{"date":"2024-01-12","current":-9.080797,"twenty":-12.136622,"median":-9.173576,"eighty":-5.162954,"marketCap":80611136},{"date":"2024-01-19","current":-7.443783,"twenty":-12.119504,"median":-9.086938,"eighty":-5.189368,"marketCap":66079197},{"date":"2024-01-26","current":-6.94959,"twenty":-12.056037,"median":-8.862874,"eighty":-5.265897,"marketCap":61692196},{"date":"2024-02-02","current":-7.706323,"twenty":-12.006103,"median":-8.582973,"eighty":-5.358906,"marketCap":68409791},{"date":"2024-02-09","current":-5.497898,"twenty":-11.971208,"median":-8.279141,"eighty":-5.454656,"marketCap":48805382},{"date":"2024-02-16","current":-4.67939,"twenty":-11.939029,"median":-8.106172,"eighty":-5.189368,"marketCap":41539412},{"date":"2024-02-23","current":-4.63306,"twenty":-11.915897,"median":-7.791263,"eighty":-5.065946,"marketCap":41128131},{"date":"2024-03-01","current":-5.714107,"twenty":-11.893737,"median":-7.613192,"eighty":-5.065946,"marketCap":50724694},{"date":"2024-03-08","current":-8.617491,"twenty":-11.891795,"median":-7.659757,"eighty":-5.094215,"marketCap":76498323},{"date":"2024-03-15","current":-6.42451,"twenty":-11.880524,"median":-7.613192,"eighty":-5.12966,"marketCap":57031008},{"date":"2024-03-22","current":-7.168217,"twenty":-11.842915,"median":-7.462714,"eighty":-5.183371,"marketCap":75538667},{"date":"2024-03-28","current":-6.569781,"twenty":-11.793205,"median":-7.382998,"eighty":-5.190398,"marketCap":69232353},{"date":"2024-04-05","current":-6.062412,"twenty":-11.727976,"median":-7.320234,"eighty":-5.219219,"marketCap":63885696},{"date":"2024-04-12","current":-5.919308,"twenty":-11.648653,"median":-7.270395,"eighty":-5.328019,"marketCap":62377665},{"date":"2024-04-19","current":-4.956607,"twenty":-11.467325,"median":-7.168217,"eighty":-5.219219,"marketCap":52232726},{"date":"2024-04-26","current":-5.106216,"twenty":-10.872247,"median":-7.057617,"eighty":-5.181486,"marketCap":53809304},{"date":"2024-05-03","current":-5.203787,"twenty":-10.575732,"median":-7.004794,"eighty":-5.110119,"marketCap":54837508},{"date":"2024-05-10","current":-4.89156,"twenty":-10.334812,"median":-6.920091,"eighty":-5.07751,"marketCap":51547257},{"date":"2024-05-17","current":-5.064674,"twenty":-10.138832,"median":-6.816961,"eighty":-5.04775,"marketCap":69917822},{"date":"2024-05-24","current":-5.034882,"twenty":-10.040205,"median":-6.769756,"eighty":-5.01517,"marketCap":69506541},{"date":"2024-05-31","current":-4.905782,"twenty":-10.013896,"median":-6.720408,"eighty":-4.982612,"marketCap":67724322},{"date":"2024-06-07","current":-4.945811,"twenty":-9.945635,"median":-6.626601,"eighty":-4.965367,"marketCap":68276920},{"date":"2024-06-14","current":-4.747756,"twenty":-9.859151,"median":-6.577272,"eighty":-4.943699,"marketCap":65542772},{"date":"2024-06-21","current":-4.638498,"twenty":-9.834825,"median":-6.527942,"eighty":-4.905297,"marketCap":64034465},{"date":"2024-06-28","current":-4.887408,"twenty":-9.833021,"median":-6.527942,"eighty":-4.896744,"marketCap":67470661},{"date":"2024-07-05","current":-4.817184,"twenty":-9.806712,"median":-6.504734,"eighty":-4.887289,"marketCap":66501232},{"date":"2024-07-12","current":-4.986137,"twenty":-9.800135,"median":-6.468725,"eighty":-4.878216,"marketCap":68833622},{"date":"2024-07-15","current":-5.055665,"twenty":-9.800135,"median":-6.445726,"eighty":-4.87855,"marketCap":69793453},{"date":"2024-08-02","current":-4.807351,"twenty":-9.796846,"median":-6.435118,"eighty":-4.877213,"marketCap":66365484},{"date":"2024-08-09","current":-4.588835,"twenty":-9.783692,"median":-6.41284,"eighty":-4.86516,"marketCap":63348871},{"date":"2024-08-16","current":-3.955696,"twenty":-9.783692,"median":-6.339457,"eighty":-4.820512,"marketCap":59632119},{"date":"2024-08-23","current":-3.896315,"twenty":-9.757383,"median":-6.270563,"eighty":-4.807351,"marketCap":58736948},{"date":"2024-08-30","current":-3.86434,"twenty":-9.645569,"median":-6.204474,"eighty":-4.781352,"marketCap":58254933},{"date":"2024-09-06","current":-3.910018,"twenty":-9.61926,"median":-6.112191,"eighty":-4.747756,"marketCap":58943526},{"date":"2024-09-13","current":-3.837391,"twenty":-9.544103,"median":-6.034647,"eighty":-4.707926,"marketCap":57848664},{"date":"2024-09-20","current":-3.727307,"twenty":-9.537044,"median":-5.97785,"eighty":-4.668296,"marketCap":56189156},{"date":"2024-09-27","current":-3.316207,"twenty":-9.52866,"median":-5.925812,"eighty":-4.63306,"marketCap":49991822},{"date":"2024-10-04","current":-3.2888,"twenty":-9.487714,"median":-5.784184,"eighty":-4.588835,"marketCap":49578667},{"date":"2024-10-11","current":-3.037299,"twenty":-9.487714,"median":-5.559672,"eighty":-4.472545,"marketCap":45787276},{"date":"2024-10-18","current":-2.923378,"twenty":-9.487714,"median":-5.461423,"eighty":-4.216084,"marketCap":44069926},{"date":"2024-10-25","current":-2.923378,"twenty":-9.26612,"median":-5.333882,"eighty":-3.973967,"marketCap":44069926},{"date":"2024-10-31","current":-2.786345,"twenty":-9.192178,"median":-5.307863,"eighty":-3.960154,"marketCap":42004148},{"date":"2024-11-08","current":-2.941649,"twenty":-9.173693,"median":-5.199834,"eighty":-3.926462,"marketCap":44345363},{"date":"2024-11-15","current":-2.689442,"twenty":-9.173505,"median":-5.189027,"eighty":-3.893574,"marketCap":43725630},{"date":"2024-11-22","current":-2.507825,"twenty":-9.109154,"median":-5.115973,"eighty":-3.863938,"marketCap":40772862},{"date":"2024-11-29","current":-2.717615,"twenty":-9.085709,"median":-5.101291,"eighty":-3.84881,"marketCap":44185701},{"date":"2024-12-06","current":-2.321954,"twenty":-9.052999,"median":-5.073692,"eighty":-3.799491,"marketCap":37752650},{"date":"2024-12-13","current":-1.917562,"twenty":-8.931511,"median":-5.06017,"eighty":-3.723653,"marketCap":31177648},{"date":"2024-12-20","current":-1.857563,"twenty":-8.853008,"median":-5.047673,"eighty":-3.619065,"marketCap":30202120},{"date":"2024-12-27","current":-1.764685,"twenty":-8.767209,"median":-5.021654,"eighty":-3.573099,"marketCap":28692014},{"date":"2025-01-03","current":-1.625368,"twenty":-8.642201,"median":-5.01517,"eighty":-3.513045,"marketCap":26426855},{"date":"2025-01-10","current":-1.838802,"twenty":-8.617491,"median":-5.008645,"eighty":-3.463472,"marketCap":29897078},{"date":"2025-01-17","current":-2.572725,"twenty":-8.517567,"median":-4.984374,"eighty":-3.373331,"marketCap":41829936},{"date":"2025-01-24","current":-2.370715,"twenty":-8.346557,"median":-4.965604,"eighty":-3.310726,"marketCap":38545455},{"date":"2025-01-31","current":-2.053117,"twenty":-8.284074,"median":-4.956607,"eighty":-3.212827,"marketCap":33381630},{"date":"2025-02-07","current":-2.238919,"twenty":-8.253306,"median":-4.940989,"eighty":-3.06772,"marketCap":36402592},{"date":"2025-02-14","current":-2.015957,"twenty":-8.160869,"median":-4.905782,"eighty":-3.026792,"marketCap":32777437},{"date":"2025-02-21","current":-2.043827,"twenty":-8.138995,"median":-4.896744,"eighty":-3.006493,"marketCap":33230582},{"date":"2025-02-28","current":-2.099568,"twenty":-8.099657,"median":-4.889484,"eighty":-2.934341,"marketCap":34136870},{"date":"2025-03-07","current":-2.146018,"twenty":-8.038556,"median":-4.87855,"eighty":-2.919724,"marketCap":34892111},{"date":"2025-03-14","current":-2.159953,"twenty":-8.005927,"median":-4.871913,"eighty":-2.813752,"marketCap":35118683},{"date":"2025-03-21","current":-1.801034,"twenty":-7.907089,"median":-4.866947,"eighty":-2.682321,"marketCap":29299223},{"date":"2025-03-28","current":-1.800101,"twenty":-7.780452,"median":-4.846639,"eighty":-2.622879,"marketCap":29284042},{"date":"2025-04-04","current":-1.82903,"twenty":-7.718678,"median":-4.817184,"eighty":-2.548971,"marketCap":29754652},{"date":"2025-04-11","current":-1.810366,"twenty":-7.669259,"median":-4.807351,"eighty":-2.494707,"marketCap":29451033},{"date":"2025-04-17","current":-1.735712,"twenty":-7.632006,"median":-4.806913,"eighty":-2.414832,"marketCap":28236557},{"date":"2025-04-25","current":-0.839954,"twenty":-7.607202,"median":-4.796544,"eighty":-2.376882,"marketCap":13664368},{"date":"2025-05-02","current":-0.521647,"twenty":-7.551589,"median":-4.752722,"eighty":-2.245719,"marketCap":8486148},{"date":"2025-05-09","current":-0.530045,"twenty":-7.466501,"median":-4.747756,"eighty":-2.177388,"marketCap":8622776},{"date":"2025-05-16","current":-0.505526,"twenty":-7.426042,"median":-4.707976,"eighty":-2.157166,"marketCap":7588954},{"date":"2025-05-23","current":-0.365063,"twenty":-7.386285,"median":-4.686306,"eighty":-2.149257,"marketCap":5480321},{"date":"2025-05-30","current":-0.393378,"twenty":-7.360388,"median":-4.668296,"eighty":-2.119771,"marketCap":5905387},{"date":"2025-06-06","current":-0.549666,"twenty":-7.332589,"median":-4.637737,"eighty":-2.099568,"marketCap":8251593},{"date":"2025-06-13","current":-0.392181,"twenty":-7.316341,"median":-4.63306,"eighty":-2.056833,"marketCap":5887424},{"date":"2025-06-20","current":-0.532797,"twenty":-7.300771,"median":-4.609845,"eighty":-2.053117,"marketCap":7998351},{"date":"2025-06-27","current":-0.511084,"twenty":-7.289347,"median":-4.571286,"eighty":-2.034537,"marketCap":7672399},{"date":"2025-07-03","current":-0.492879,"twenty":-7.259023,"median":-4.506472,"eighty":-1.991406,"marketCap":7399101},{"date":"2025-07-11","current":-0.528288,"twenty":-7.195283,"median":-4.389384,"eighty":-1.94521,"marketCap":7930653},{"date":"2025-07-18","current":-0.557015,"twenty":-7.170822,"median":-4.18175,"eighty":-1.91115,"marketCap":8361912},{"date":"2025-07-25","current":-0.542818,"twenty":-7.116406,"median":-4.001374,"eighty":-1.881987,"marketCap":8148790},{"date":"2025-08-01","current":-0.462648,"twenty":-7.091556,"median":-3.972293,"eighty":-1.853811,"marketCap":6945276},{"date":"2025-08-08","current":-0.502341,"twenty":-7.039039,"median":-3.955696,"eighty":-1.829566,"marketCap":6318446},{"date":"2025-08-15","current":-1.11677,"twenty":-7.015013,"median":-3.928289,"eighty":-1.810366,"marketCap":14046731},{"date":"2025-08-22","current":-1.175134,"twenty":-7.006256,"median":-3.910018,"eighty":-1.798683,"marketCap":14780832},{"date":"2025-08-29","current":-1.08871,"twenty":-6.960631,"median":-3.889463,"eighty":-1.782371,"marketCap":13693798},{"date":"2025-09-05","current":-1.066138,"twenty":-6.940264,"median":-3.868908,"eighty":-1.769697,"marketCap":13409881},{"date":"2025-09-12","current":-0.906383,"twenty":-6.917299,"median":-3.862331,"eighty":-1.745683,"marketCap":11400489},{"date":"2025-09-19","current":-0.936024,"twenty":-6.885877,"median":-3.848353,"eighty":-1.727072,"marketCap":11773310},{"date":"2025-09-26","current":-0.967225,"twenty":-6.839125,"median":-3.809527,"eighty":-1.460474,"marketCap":12165754},{"date":"2025-10-03","current":-1.053027,"twenty":-6.813143,"median":-3.783279,"eighty":-1.137571,"marketCap":13244974},{"date":"2025-10-10","current":-1.237502,"twenty":-6.788993,"median":-3.727307,"eighty":-1.12949,"marketCap":15565298},{"date":"2025-10-17","current":-1.024946,"twenty":-6.76879,"median":-3.686198,"eighty":-1.120137,"marketCap":12891775},{"date":"2025-10-24","current":-0.939534,"twenty":-6.749312,"median":-3.590621,"eighty":-1.104352,"marketCap":11817460},{"date":"2025-10-31","current":-5.148132,"twenty":-6.716708,"median":-3.589534,"eighty":-1.099571,"marketCap":64753209},{"date":"2025-11-07","current":-1.892719,"twenty":-6.656725,"median":-3.544596,"eighty":-1.101463,"marketCap":23806615},{"date":"2025-11-14","current":-2.446921,"twenty":-6.626601,"median":-3.5023,"eighty":-1.103492,"marketCap":28717059},{"date":"2025-11-21","current":-1.944844,"twenty":-6.606869,"median":-3.463472,"eighty":-1.104352,"marketCap":22824686},{"date":"2025-11-28","current":-2.043621,"twenty":-6.587138,"median":-3.425742,"eighty":-1.107316,"marketCap":23983940},{"date":"2025-12-05","current":-2.35582,"twenty":-6.574276,"median":-3.358472,"eighty":-1.113245,"marketCap":27647903},{"date":"2025-12-12","current":-3.019626,"twenty":-6.553045,"median":-3.316207,"eighty":-1.116199,"marketCap":35438329},{"date":"2025-12-19","current":-2.137793,"twenty":-6.527942,"median":-3.243133,"eighty":-1.119015,"marketCap":25089135},{"date":"2025-12-26","current":-2.080983,"twenty":-6.524653,"median":-3.176227,"eighty":-1.123804,"marketCap":24422414},{"date":"2026-01-02","current":-2.099408,"twenty":-6.511499,"median":-3.101522,"eighty":-1.12949,"marketCap":24638648},{"date":"2026-01-09","current":-2.221728,"twenty":-6.504734,"median":-3.060412,"eighty":-1.12949,"marketCap":26074201},{"date":"2026-01-16","current":-2.13984,"twenty":-6.495056,"median":-3.033553,"eighty":-1.130611,"marketCap":25113161},{"date":"2026-01-23","current":-2.069211,"twenty":-6.49239,"median":-3.01718,"eighty":-1.136,"marketCap":24284265},{"date":"2026-01-30","current":-1.919766,"twenty":-6.454926,"median":-3.013363,"eighty":-1.137646,"marketCap":22530368},{"date":"2026-02-06","current":-1.733982,"twenty":-6.428753,"median":-2.969787,"eighty":-1.161067,"marketCap":20350010},{"date":"2026-02-13","current":-1.899293,"twenty":-6.415174,"median":-2.923378,"eighty":-1.169405,"marketCap":22290108},{"date":"2026-02-20","current":-1.407702,"twenty":-6.41284,"median":-2.923378,"eighty":-1.173092,"marketCap":16520786},{"date":"2026-02-27","current":-1.68406,"twenty":-6.373511,"median":-2.907391,"eighty":-1.18307,"marketCap":19764131},{"date":"2026-03-06","current":-1.666788,"twenty":-6.347157,"median":-2.832023,"eighty":-1.198842,"marketCap":19561422},{"date":"2026-03-13","current":-1.602016,"twenty":-6.337936,"median":-2.800625,"eighty":-1.210211,"marketCap":18801263},{"date":"2026-03-20","current":-1.36668,"twenty":-6.318494,"median":-2.717615,"eighty":-1.227754,"marketCap":16039352},{"date":"2026-03-27","current":-1.31918,"twenty":-6.286175,"median":-2.680541,"eighty":-1.251532,"marketCap":15481902},{"date":"2026-04-02","current":-1.245392,"twenty":-6.265359,"median":-2.664029,"eighty":-1.244158,"marketCap":14454023},{"date":"2026-04-10","current":-1.225823,"twenty":-6.247146,"median":-2.620421,"eighty":-1.218208,"marketCap":14226900},{"date":"2026-04-17","current":-1.164532,"twenty":-6.209886,"median":-2.570403,"eighty":-1.20262,"marketCap":13515555},{"date":"2026-04-24","current":-1.166721,"twenty":-6.171236,"median":-2.563437,"eighty":-1.174026,"marketCap":13540960},{"date":"2026-05-01","current":-1.140453,"twenty":-6.122147,"median":-2.524515,"eighty":-1.165408,"marketCap":13236098},{"date":"2026-05-08","current":-1.118563,"twenty":-6.057883,"median":-2.498422,"eighty":-1.149209,"marketCap":12982046},{"date":"2026-05-15","current":-1.214157,"twenty":-6.044513,"median":-2.460923,"eighty":-1.153587,"marketCap":12982976},{"date":"2026-05-22","current":-1.167077,"twenty":-6.017625,"median":-2.414832,"eighty":-1.147254,"marketCap":12479554},{"date":"2026-05-29","current":-1.095219,"twenty":-5.990544,"median":-2.405465,"eighty":-1.145316,"marketCap":11711174},{"date":"2026-06-04","current":-0.996104,"twenty":-5.984355,"median":-2.391613,"eighty":-1.140453,"marketCap":10651339}],"updateTime":1780688373719},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"INTS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2633722871","title":"Intensity Therapeutics Q1 FY26 net loss narrows to $2.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633722871","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633722871?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:46","pubTimestamp":1778186790,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics posted a Q1 net loss of USD 2.4 million, narrowing from USD 3.3 million a year earlier; loss per share improved to USD 0.96 from USD 5.51.R&D expense fell to USD 1.2 million from USD 2.2 million, reflecting lower INVINCIBLE-3 trial costs; G&A edged up to USD 1.3 million from USD 1.2 million on an estimated bonus accrual.Cash and cash equivalents declined to USD 10.2 million at March 31 from USD 11.9 million at year-end.INVINCIBLE-4 early TNBC data showed pCR in 5 of 7 patients  receiving INT230-6 before standard of care versus 2 of 6 (33%) on standard of care alone; grade 3+ adverse events were 44% lower in the INT230-6 arm.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intensity Therapeutics Inc. published the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL4WgNr3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INTS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633179529","title":"BRIEF-Intensity Therapeutics Q1 Operating Income USD -2.526 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633179529","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633179529?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:07","pubTimestamp":1778184435,"startTime":"0","endTime":"0","summary":"BRIEF-Intensity Therapeutics Q1 Operating Income USD -2.526 Million\n\n\nMay 07 (Reuters) - Intensity Therapeutics Q1 basic EPS USD -0.96.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLX34BFA8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INTS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633762881","title":"Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633762881","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633762881?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:06","pubTimestamp":1778184391,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nTUA65VLGR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632693136","title":"Intensity Therapeutics announces annual shareholder meeting webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2632693136","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632693136?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:17","pubTimestamp":1777580234,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics scheduled 2026 annual stockholders meeting for June 16, 2026, to be held virtually via live audio webcast.Shareholders will vote to elect two directors to three-year terms expiring in 2029.Investors will also vote on amendments to increase share authorization under 2021 Stock Incentive Plan by 150,000 shares, 2024 Employee Stock Purchase Plan by 25,000 shares.Proposal set includes authorization for postponement or adjournment of meeting to solicit additional proxies or establish quorum.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intensity Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDLF24Yp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623958371","title":"Intensity Therapeutics Inc : Benchmark Adjusts Target Price to $12 From $1.50 to Reflect Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2623958371","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623958371?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:15","pubTimestamp":1774955718,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nFWN40J10Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623189337","title":"U.S. Tariff and Trade Policy Risks Threaten Intensity Therapeutics’ Supply Chain, Costs, and Stock Valuation","url":"https://stock-news.laohu8.com/highlight/detail?id=2623189337","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623189337?lang=en_us&edition=fundamental","pubTime":"2026-03-29 14:01","pubTimestamp":1774764067,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics, Inc. (INTS) has disclosed a new risk, in the Regulation category. Changes in U.S. tariff and import/export regulations coul...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/u-s-tariff-and-trade-policy-risks-threaten-intensity-therapeutics-supply-chain-costs-and-stock-valuation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/u-s-tariff-and-trade-policy-risks-threaten-intensity-therapeutics-supply-chain-costs-and-stock-valuation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","INTS","BK4139","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622808891","title":"Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2622808891","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622808891?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:12","pubTimestamp":1774642366,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nTUA18PLVF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622416870","title":"Intensity Therapeutics FY2025 net loss narrows 28.66% to $(11.6) million; operating expenses drop 27.81% to $12.0 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622416870","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622416870?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:02","pubTimestamp":1774641762,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics published an annual report  reporting a net loss of USD 11.6 million and a loss from operations of USD 12 million.Research and development expense fell 35% to USD 6.8 million, driven mainly by lower clinical trial costs after pausing new site activations and patient enrollment in the INVINCIBLE-3 Phase 3 sarcoma study due to funding constraints.General and administrative expense declined 15% to USD 5.2 million, reflecting lower legal, accounting and consulting costs alongside reduced stock-based compensation.Cash and cash equivalents were USD 11.9 million, and management said it expects this to fund the current operating plan into the second quarter of 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intensit","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDLb218J5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INTS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621640330","title":"Intensity Therapeutics issued new patent in the US","url":"https://stock-news.laohu8.com/highlight/detail?id=2621640330","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621640330?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:12","pubTimestamp":1774354363,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics (INTS) provided an update on its patent portfolio including the recent issuance in December 2025 of a new patent in the U.S....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/intensity-therapeutics-issued-new-patent-in-the-us-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/intensity-therapeutics-issued-new-patent-in-the-us-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LENZ","INTS","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621064671","title":"Intensity Therapeutics wins US patent 12,496,345 for cancer treatment method","url":"https://stock-news.laohu8.com/highlight/detail?id=2621064671","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621064671?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:04","pubTimestamp":1774353897,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics said a new U.S. patent, No. 12,496,345, titled “A Method of Treating Cancer,” was issued in December 2025.The company said the patent covers a method of treating cancer and an intratumoral formulation.Intensity Therapeutics reported it now has four issued U.S. patents and one pending U.S. patent application.The company said its patents have been granted in 41 countries.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL3srrvK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621081972","title":"Intensity Therapeutics Inc Files for Common Stock Offering of up to $60 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2621081972","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621081972?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:02","pubTimestamp":1774296165,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B0J1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621081900","title":"Intensity Therapeutics expands ATM equity offering capacity to USD 60 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621081900","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621081900?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:02","pubTimestamp":1774296162,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics filed a prospectus supplement to increase the capacity of its at-the-market equity distribution program to USD 60.0 million.The program operates under an at-the-market offering agreement with H.C. Wainwright & Co.Any sales under the program are at the company’s discretion and may depend on the market price of its common stock.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intensity Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 23, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL9SDqlx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621081127","title":"Intensity Therapeutics Inc - Expanded Atm Facility Intended to Enhance Financial Flexibility - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2621081127","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621081127?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:02","pubTimestamp":1774296161,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B0J0:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INTS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619100191","title":"Alliance Global Partners Sticks to Their Buy Rating for Intensity Therapeutics, Inc. (INTS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2619100191","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619100191?lang=en_us&edition=fundamental","pubTime":"2026-03-13 19:39","pubTimestamp":1773401944,"startTime":"0","endTime":"0","summary":"In a report released today, James Molloy from Alliance Global Partners reiterated a Buy rating on Intensity Therapeutics, Inc., with a price target...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/alliance-global-partners-sticks-to-their-buy-rating-for-intensity-therapeutics-inc-ints-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/alliance-global-partners-sticks-to-their-buy-rating-for-intensity-therapeutics-inc-ints-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619777158","title":"BUZZ-U.S. STOCKS ON THE MOVE  -Natera, Pacira BioSciences, Kezar Life Sciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2619777158","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619777158?lang=en_us&edition=fundamental","pubTime":"2026-03-12 23:59","pubTimestamp":1773331150,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE  -Natera, Pacira BioSciences, Kezar Life SciencesWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning Ne","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nL6N40014H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","XOMX","NOG","NTRA","DG","MUR","AAL","KKR","KMLI","CUBI","SPRC","GFS","BX","DKS","LU1116320737.USD","XOMZ","XOMO","CASH","BBW","GYRE","CE","CF","MOS","WLTH","GIII","INTS","SM","IE0002270589.USD","DOW","RPID","JBL","LU1868837565.USD","OWL","BMBL","LUV","AALG","DAL","MELI","ARES","TBBK","LU0175139822.USD","SG9999014898.SGD","UAL","KZR","BK4121","LU0320765646.SGD","SG9999014906.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2619153409","title":"Intensity Therapeutics Updates Breast Cancer Trial, Files To Resume Enrollment Following Study Pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2619153409","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619153409?lang=en_us&edition=fundamental","pubTime":"2026-03-12 23:15","pubTimestamp":1773328500,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics reports early data showing higher response rates with INT230-6 in triple-negative breast cancer patients.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/12/doctor--patient--breast-cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/12/doctor--patient--breast-cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/26/03/51216612/intensity-therapeutics-updates-breast-cancer-trial-files-to-resume-enrollment-following-study-pause","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/03/51216612/intensity-therapeutics-updates-breast-cancer-trial-files-to-resume-enrollment-following-study-pause","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4007","LENZ","SOC","BK4539","BK4139","INTS","BK4213"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618131894","title":"BUZZ-Intensity Therapeutics rises as breast cancer drug shows early promise","url":"https://stock-news.laohu8.com/highlight/detail?id=2618131894","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618131894?lang=en_us&edition=fundamental","pubTime":"2026-03-12 19:40","pubTimestamp":1773315610,"startTime":"0","endTime":"0","summary":"BUZZ-Intensity Therapeutics rises as breast cancer drug shows early promise** Shares of biotech firm Intensity Therapeutics INTS.O rise about 3.5% to $8.19 premarket** Co says its experimental drug, INT230-6, showed encouraging early results in a small study in triple-negative breast cancer - an aggressive form with limited treatment options** In a mid-stage study, five of seven patients given INT230-6 before standard chemo and immunotherapy had no trace of cancer at surgery vs two of six on standard treatment alone, a result linked to lower relapse risk, INTS says** Co says patients receiving INT230-6 had fewer serious side effects than those on standard care** Trial enrollment was paused last year after skin irritation cases; co says it has submitted a revised plan to resume the study at a lower dose** Shares down ~77% in 2025  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nL4N400143:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618913944","title":"Intensity Therapeutics reports 71% pCR in INT230-6 arm and 44% fewer grade 3+ adverse events in INVINCIBLE-4 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2618913944","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618913944?lang=en_us&edition=fundamental","pubTime":"2026-03-12 19:31","pubTimestamp":1773315065,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics reported preliminary Phase 2 INVINCIBLE-4 data in presurgical triple-negative breast cancer showing a pathological complete response  rate of 71% (5/7) in patients who received INT230-6 before standard of care, versus 33% (2/6) with standard of care alone. The company said Cohort A had 44% fewer grade 3 or higher adverse events than Cohort B. Safety tallies through March 2, 2026 showed 14 grade 3+ adverse events in Cohort A versus 25 in Cohort B. Intensity Therapeutics said it submitted a protocol amendment to Swissmedic and the Swiss Ethics Committee to resume enrollment using a lower drug volume per tumor volume ratio and a single INT230-6 injection.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intensity Ther","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL765g5z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618435139","title":"Intensity Therapeutics Inc - Protocol Amendment Proposes Lower Drug Volume and Single Int230-6 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2618435139","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618435139?lang=en_us&edition=fundamental","pubTime":"2026-03-12 19:30","pubTimestamp":1773315000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nTUA8HCLK9:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618391991","title":"Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer Invincible-4 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2618391991","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618391991?lang=en_us&edition=fundamental","pubTime":"2026-03-12 19:30","pubTimestamp":1773315000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nTUA8HCLK9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INTS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":44,"code":"91000000","status":"200"}]}}